Basir Mansoor

ORCID: 0009-0007-3581-3422
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Circular RNAs in diseases
  • Genomics, phytochemicals, and oxidative stress
  • Endoplasmic Reticulum Stress and Disease
  • MicroRNA in disease regulation

The University of Texas at Dallas
2023-2025

The University of Texas Southwestern Medical Center
2025

Chronic inflammation is a cancer hallmark and chronic exposure to interleukin-1 (IL-1) transforms castration-sensitive prostate (PCa) cells into more fit castration-insensitive PCa cells. p62 scaffold protein that protects from nutrient deprivation via autophagy cytotoxic reactive oxygen NFκB NRF2 antioxidant signaling. Herein, we report the LNCaP cell line acquires high basal accumulation of p62-KEAP1 complex when chronically exposed IL-1. promotes non-canonical signaling by binding...

10.3390/cells14030192 article EN cc-by Cells 2025-01-28

Abstract Objective To investigate the impact of severe obesity on severity pediatric obstructive sleep apnea (OSA). Study Design Retrospective case series. Setting Tertiary stand‐alone hospital. Methods Consecutive children with (≥95th percentile body mass index [BMI]) who underwent full‐night polysomnography between January 2021 and December were analyzed. Patients categorized into BMI <120% 95th percentile) (≥120% BMI). The association OSA was assessed using multiple logistic...

10.1002/ohn.1295 article EN Otolaryngology 2025-05-14

Abstract Prostate cancer (PCa) is the second most common cause of cancer-related death among American men. Androgen Receptor (AR) transcriptional activity required for PCa tumor growth. Thus, androgen deprivation therapy (ADT) a first line therapy. However, 10-20% patients will inevitably develop lethal castration-resistant (CRPC). we must uncover mechanisms that drive CPRC. Chronic inflammation known hallmark initiation and progression. Using LNCaP human cell line, have shown chronic...

10.1158/1538-7445.am2023-287 article EN Cancer Research 2023-04-04
Coming Soon ...